[{"address1": "4870 Sadler Road", "address2": "Suite 300", "city": "Glen Allen", "state": "VA", "zip": "23060", "country": "United States", "phone": "804 487 8196", "website": "https://www.adialpharma.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Adial Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment or prevention of addiction and related disorders. The company's lead product is AD04, a serotonin-3 antagonist, which is in Phase 3 clinical trials for the treatment of alcohol use disorder. It is also involved in the development of drug candidates for non-opioid pain reduction and other diseases and disorders. The company was founded in 2010 and is based in Glen Allen, Virginia.", "fullTimeEmployees": 4, "maxAge": 86400, "priceHint": 4, "previousClose": 1.1, "open": 1.13, "dayLow": 1.06, "dayHigh": 1.17, "regularMarketPreviousClose": 1.1, "regularMarketOpen": 1.13, "regularMarketDayLow": 1.06, "regularMarketDayHigh": 1.17, "beta": 1.287, "forwardPE": -0.65497077, "volume": 292758, "regularMarketVolume": 292758, "averageVolume": 2695650, "averageVolume10days": 142390, "averageDailyVolume10Day": 142390, "bid": 1.1, "ask": 1.15, "bidSize": 100, "askSize": 100, "marketCap": 4741307, "fiftyTwoWeekLow": 0.77, "fiftyTwoWeekHigh": 14.0, "fiftyDayAverage": 1.5796, "twoHundredDayAverage": 1.86085, "currency": "USD", "enterpriseValue": -283805, "floatShares": 4115791, "sharesOutstanding": 4233310, "sharesShort": 132318, "sharesShortPriorMonth": 1009702, "sharesShortPreviousMonthDate": 1713139200, "dateShortInterest": 1715731200, "sharesPercentSharesOut": 0.0313, "heldPercentInsiders": 0.038680002, "heldPercentInstitutions": 0.04165, "shortRatio": 0.27, "shortPercentOfFloat": 0.0323, "impliedSharesOutstanding": 4233310, "bookValue": 1.51, "priceToBook": 0.74172187, "lastFiscalYearEnd": 1703980800, "nextFiscalYearEnd": 1735603200, "mostRecentQuarter": 1711843200, "netIncomeToCommon": -11238567, "trailingEps": -4.98, "forwardEps": -1.71, "lastSplitFactor": "1:25", "lastSplitDate": 1691366400, "enterpriseToEbitda": 0.044, "52WeekChange": -0.8052174, "SandP52WeekChange": 0.26238096, "exchange": "NCM", "quoteType": "EQUITY", "symbol": "ADIL", "underlyingSymbol": "ADIL", "shortName": "Adial Pharmaceuticals, Inc", "longName": "Adial Pharmaceuticals, Inc.", "firstTradeDateEpochUtc": 1532698200, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EDT", "uuid": "a144d6a7-1775-3bb1-b1ca-599a0edca1eb", "messageBoardId": "finmb_112638788", "gmtOffSetMilliseconds": -14400000, "currentPrice": 1.12, "recommendationMean": 2.5, "recommendationKey": "buy", "totalCash": 5025110, "totalCashPerShare": 1.187, "ebitda": -6463630, "quickRatio": 8.93, "currentRatio": 9.483, "returnOnAssets": -0.76329005, "returnOnEquity": -2.97258, "freeCashflow": -3287655, "operatingCashflow": -6134232, "financialCurrency": "USD", "trailingPegRatio": null, "__fetch_time": "2024-06-24"}]